$18.83
0[0.00%]
Last update: 4:00PM Get Real Time Here
ArriVent BioPharma
(NASDAQ:AVBP)ArriVent BioPharma Stock (NASDAQ:AVBP), Analyst Ratings, Price Targets, Predictions
ArriVent BioPharma Inc has a consensus price target of $29.25, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on June 6, 2024, May 9, 2024, and April 30, 2024. With an average price target of $25 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 32.77% upside for ArriVent BioPharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citigroup
Jefferies
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for ArriVent BioPharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/06/2024 | Buy Now | 32.77% | HC Wainwright & Co. | Robert Burns | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 32.77% | HC Wainwright & Co. | Robert Burns | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | 32.77% | HC Wainwright & Co. | Robert Burns | → $25 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | 59.32% | Citigroup | Yigal Nochomovitz | → $30 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | 85.87% | Jefferies | Kelly Shi | → $35 | Initiates | → Buy | Get Alert |
| 02/20/2024 | Buy Now | 43.39% | Goldman Sachs | Corinne Johnson | → $27 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for ArriVent BioPharma (AVBP) stock?
The latest price target for ArriVent BioPharma (NASDAQ:AVBP) was reported by HC Wainwright & Co. on June 6, 2024. The analyst firm set a price target for $25.00 expecting AVBP to rise to within 12 months (a possible 32.77% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ArriVent BioPharma (AVBP)?
The latest analyst rating for ArriVent BioPharma (NASDAQ:AVBP) was provided by HC Wainwright & Co., and ArriVent BioPharma reiterated their buy rating.
When was the last upgrade for ArriVent BioPharma (AVBP)?
There is no last upgrade for ArriVent BioPharma
When was the last downgrade for ArriVent BioPharma (AVBP)?
There is no last downgrade for ArriVent BioPharma.
When is the next analyst rating going to be posted or updated for ArriVent BioPharma (AVBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ArriVent BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ArriVent BioPharma was filed on June 6, 2024 so you should expect the next rating to be made available sometime around June 6, 2025.
Is the Analyst Rating ArriVent BioPharma (AVBP) correct?
While ratings are subjective and will change, the latest ArriVent BioPharma (AVBP) rating was a reiterated with a price target of $25.00 to $25.00. The current price ArriVent BioPharma (AVBP) is trading at is $18.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.